The Transplant Appeal: When the Carrier Says No to Organ Coverage

There is a number every transplant patient eventually learns by heart, and it is not their MELD score or their UNOS waitlist position. It is the date the carrier first used the phrase "not a covered benefit at this facility." For one 58-year-old former HVAC installer in suburban Cleveland with polycystic kidney disease, that date was October 14, in a letter that informed him that the transplant center his nephrologist had referred him to, where his living donor evaluation was already underway, was not in his commercial plan's contracted transplant network. The alternative network facility was 287 miles away in Pittsburgh. His donor, his sister, had taken three days off work for the evaluation. His MELD-equivalent kidney measure was advancing. The letter ran four pages and used the word "network" eleven times. It used the word "transplant" once.

Transplant coverage in the United States runs on a parallel-network architecture that almost no commercial-insurance member discovers until they need it. Most large commercial plans contract with a designated transplant network, often a third-party administrator such as Optum Transplant or INTERLINK, that operates separately from the plan's general provider network. A surgeon, hospital, or transplant center in the commercial network for general care may not be in the transplant network for transplant procedures. The result is that the patient who has been receiving in-network nephrology, hepatology, or cardiology care from a particular health system can be told, sometimes weeks before a scheduled procedure, that the transplant itself must be performed at a different facility.

This article is the working guide to the transplant coverage architecture, the common denial patterns, the criteria the carrier is supposed to apply, and the appeal that survives them. The clinical focus stays on non-oncology transplants: kidney transplants for polycystic kidney disease, diabetic nephropathy, hypertensive nephropathy, IgA nephropathy, and the other principal indications; liver transplants for non-alcoholic steatohepatitis (NASH), alcohol-related liver disease in long-term recovery, primary biliary cholangitis, and other non-oncology indications; heart transplants for ischemic cardiomyopathy, dilated cardiomyopathy, and congenital heart disease; and lung transplants for chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and cystic fibrosis. Oncology-driven transplants follow a different evidentiary frame and are outside this article's scope.

The architecture: UNOS, OPTN, the transplant centers, and the carrier networks

The United States transplant system runs on a federally chartered framework. The Organ Procurement and Transplantation Network, OPTN, is the national system established under Section 372 of the National Organ Transplant Act of 1984, codified at 42 USC 274. The United Network for Organ Sharing, UNOS, has held the OPTN contract continuously since the network's creation, with HRSA management of an ongoing transition to a modernized OPTN governance structure under the OPTN Modernization Initiative. Transplant center membership, candidate listing protocols, organ allocation rules, and reporting requirements are set by OPTN policy under 42 CFR Part 121.

Carrier networks are layered on top of this federal system, not integrated with it. A patient who is medically eligible for transplant under OPTN criteria and is listed at a UNOS member transplant center may still face commercial coverage denial because the listed center is not in the carrier's contracted transplant network. The federal system governs eligibility and allocation. The commercial network governs payment. The two systems do not communicate.

The patient typically discovers this asymmetry only when the transplant referral has been made and the prior authorization is pending. By that point the workup is well underway, donor evaluations may have begun, and the clock on the disease trajectory is running. The leverage point is to identify the asymmetry early, before the coverage denial converts the clinical plan.

The four denial patterns

The denial taxonomy in transplant coverage is small. Most denials fall into one of four patterns.

The first is the network-facility denial. The carrier acknowledges coverage of the transplant category but designates a specific facility or set of facilities as the only in-network option. The patient's selected center is out-of-network, and full-cost-share or full-cost responsibility applies. This is the Cleveland-to-Pittsburgh fact pattern.

The second is the medical-necessity denial. The carrier disputes that transplant is the appropriate intervention for this patient at this stage. The dispute may center on disease severity (MELD score for liver, eGFR trajectory for kidney, NYHA class for heart), comorbidity contraindications, or the candidate's adherence and psychosocial profile. The denial cites internal medical-necessity criteria, often diverging from the UNOS or OPTN candidate-selection criteria the transplant center applied.

The third is the experimental-or-investigational denial. This applies primarily to specific procedures: combined organ transplants (heart-kidney, liver-kidney), pediatric transplants in specific scenarios, transplants for less-common indications, and emerging surgical techniques. The carrier classifies the procedure as not yet established and denies on that basis.

The fourth is the donor-related denial. Living-donor evaluation and surgery, donor-related medical costs, and donor follow-up care are governed by a separate set of carrier rules and federal protections. Denial of donor-evaluation coverage, donor-surgery coverage, or donor follow-up care raises questions under the Living Donor Protection Act of 2024 and the National Organ Transplant Act framework.

What the carrier policy actually says, and what UNOS actually requires

Commercial carrier transplant bulletins are typically dense and reference both internal medical-necessity criteria and external standards. The external standards usually include OPTN policies (binding on transplant centers under 42 CFR 121.4), candidate-selection criteria specific to each organ, and society-published guidance from the American Society of Transplantation, the American Society of Transplant Surgeons, and the organ-specific specialty societies.

For kidney transplants, the criteria address eGFR threshold (typically transplant evaluation appropriate at eGFR below 20 mL/min/1.73 m2, listing at eGFR below 20, with some allocation priority at lower thresholds), absence of active infection, absence of psychosocial contraindications, and adequacy of social support. The KDIGO 2020 Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation is the principal society guidance.

For liver transplants, the MELD-Na score (Model for End-Stage Liver Disease, sodium-adjusted) is the principal allocation criterion, with regional variation in actual transplant MELD scores. The AASLD (American Association for the Study of Liver Diseases) practice guidance on evaluation for liver transplantation is the society source.

For heart transplants, the ISHLT (International Society for Heart and Lung Transplantation) listing criteria and the ACC/AHA heart failure guidelines provide the framework. NYHA Class III-IV refractory heart failure with optimal medical therapy is the typical indication.

For lung transplants, the ISHLT International Consensus Document on the Selection of Lung Transplant Candidates is the principal source, with disease-specific listing criteria for COPD, idiopathic pulmonary fibrosis, cystic fibrosis, and pulmonary arterial hypertension.

Where the carrier's internal medical-necessity criteria diverge from the OPTN policies and society guidance, the appeal cites the federal and society framework. The carrier's authority to set its own criteria does not extend to setting them in conflict with the OPTN policies that bind the transplant center.

Exhibit 1: The transplant network architecture

The architecture is easier to read in a single table than in narrative form.

| Layer | Function | Who runs it | Where the patient encounters it | |---|---|---|---| | OPTN/UNOS | National waitlist, allocation policy, candidate-listing protocols | UNOS under federal contract with HRSA | At listing and during waitlist period | | Transplant center | Candidate evaluation, surgical performance, post-transplant care | Hospital-based programs, UNOS members | Throughout evaluation, surgery, and follow-up | | Carrier transplant network | Contracted facilities for payment purposes | Plan or third-party administrator (Optum, INTERLINK, others) | At prior authorization and at payment | | Carrier medical-necessity policy | Disease-specific criteria for transplant coverage | Plan medical-policy team | At prior authorization and at denial | | Federal donor protections | NOTA, Living Donor Protection Act, OPTN policy on donors | HRSA, OPTN | At donor evaluation and post-donation |

Action title for designer: "Five layers, two of them federal and three of them commercial. The federal layers decide who can be transplanted. The commercial layers decide where and at whose expense."

Exhibit 2: Common denial patterns mapped to the controlling framework

| Denial pattern | Carrier's stated basis | Controlling external framework | Appeal anchor | |---|---|---|---| | Network facility | Plan or TPA network design | NOTA candidate-choice principle; state any-willing-provider laws where applicable | Continuity of care, established clinical relationship, donor scheduling | | Medical necessity (kidney) | Internal criteria | KDIGO 2020 Guideline; OPTN listing criteria | Society guidance, treating nephrologist's documentation | | Medical necessity (liver) | Internal criteria; MELD threshold | AASLD practice guidance; OPTN/MELD allocation policy | Trajectory of MELD, complications, society guidance | | Medical necessity (heart) | Internal criteria | ISHLT listing criteria; ACC/AHA heart failure guideline | NYHA class, optimal medical therapy failure | | Medical necessity (lung) | Internal criteria | ISHLT International Consensus Document | Disease-specific listing criteria | | Experimental designation | Insufficient evidence base | OPTN policy permitting procedure; peer-reviewed literature | Society endorsement, OPTN authorization | | Donor evaluation/surgery | Plan design | NOTA; Living Donor Protection Act 2024; OPTN donor policy | Federal donor protections; ACA preventive frame where applicable | | Psychosocial contraindication | Carrier review | Society guidance on psychosocial evaluation; transplant center evaluation | Treating team's psychosocial evaluation, family support documentation |

Action title for designer: "Every denial pattern has a federal or society framework above it. The appeal does not invent the standard; it points the carrier to the standard the transplant center already applied."

Exhibit 3: The candidate-evaluation evidence stack, by organ

The clinical evidence supporting transplant candidacy is well established for the principal non-oncology indications. The appeal's job is to assemble and cite it cleanly.

| Organ | Principal society guidance | Allocation criterion | Common comorbidity considerations | |---|---|---|---| | Kidney | KDIGO 2020 Clinical Practice Guideline | OPTN kidney allocation policy; CPRA-adjusted | Cardiovascular risk, infection screening, malignancy clearance | | Liver | AASLD Practice Guidance on Evaluation for Liver Transplantation | MELD-Na score | Cardiac clearance, infection, psychiatric stability | | Heart | ISHLT Listing Criteria; ACC/AHA Heart Failure Guidelines | OPTN heart status (1-6) | Pulmonary hypertension reversibility, BMI, frailty | | Lung | ISHLT International Consensus Document on Selection of Lung Transplant Candidates | OPTN Lung Allocation Score (LAS) | BMI, six-minute walk distance, infection profile | | Pancreas | American Diabetes Association guidance; OPTN pancreas allocation | OPTN pancreas/kidney allocation | C-peptide threshold, glycemic control history | | Intestine | UNOS intestine guidance; pediatric and adult criteria | OPTN intestine allocation | TPN dependence, complications of long-term TPN |

Action title for designer: "The clinical evidence base is durable and society-endorsed. The appeal that wins reads the carrier's denial against the framework the transplant center already used to list the patient."

The Living Donor Protection Act and the donor pathway

The Living Donor Protection Act of 2024 was the federal framework consolidating earlier patchwork protections for living donors. The Act prohibits life, disability, and long-term-care insurers from denying coverage or imposing higher premiums solely on the basis of living-donor status, clarifies that living-donor surgery and recovery qualify as a serious health condition under the Family and Medical Leave Act, and directs HHS to update donor-related public information. The Act does not require health insurers to cover donor evaluation or surgery for the donor; that coverage runs through the recipient's plan, under the rule that donor medical costs related to transplantation of a covered recipient are themselves covered by the recipient's plan.

Donor-related denials by the recipient's plan are appealable on the basis that the donor's medical costs are an inseparable component of the recipient's covered transplant. The OPTN policy framework and standard transplant-network contract terms recognize this. A carrier that purports to cover the recipient's transplant but exclude the donor's evaluation or surgery should be challenged on the integration of the two.

The network-facility appeal: continuity and access

The network-facility denial is the most procedurally focused of the four patterns. The appeal does not relitigate medical necessity; it argues that the in-network designation should be expanded to include the patient's chosen center, or that an in-network exception should apply.

Three arguments are typical. The first is continuity of care: the patient has an established clinical relationship at the chosen center, including completed workup elements, established donor evaluation, and integration with referring specialists. Disrupting that continuity has clinical cost. The second is access: the carrier's designated network facility may be geographically inaccessible, particularly for the multi-month pre-transplant workup, the transplant admission itself, and the intensive post-transplant follow-up. ACA network-adequacy rules at 45 CFR 156.230 require networks adequate to ensure access without unreasonable delay; the same principle informs ERISA fiduciary duty analyses. The third is the donor: in living-donor cases, the donor's geographic and medical situation is part of the access analysis. A donor who has completed evaluation at the chosen center cannot easily be redirected.

The appeal asks for either expansion of the in-network designation to include the chosen center or, more commonly, an in-network exception applying in-network cost-sharing to the chosen center for this specific case.

The medical-necessity appeal: aligning to the transplant center's clinical record

The medical-necessity appeal anchors on the transplant center's own evaluation. The center has already applied society guidance and OPTN criteria in listing the patient. The appeal references that evaluation, attaches the relevant clinical notes (with patient authorization), and asks the carrier to recognize that the carrier's internal criteria, where they diverge, are not the controlling standard. Apellica's senior reviewers build the medical-necessity counter-paragraph for every transplant case the desk takes on, with the OPTN policy cite, the relevant society guidance (KDIGO, AASLD, ISHLT, as applicable), the disease-severity metric drawn from the chart, and the transplant center's listing-evaluation documentation.

Why a self-prepared appeal usually stalls

Transplant appeals run across three architectures simultaneously: the OPTN/UNOS federal framework, the transplant center's clinical record, and the carrier's separate transplant network (often a third-party administrator like Optum Transplant or INTERLINK with its own contracted facility list). The mapped library Apellica has catalogued (more than two hundred carrier-by-denial-type cells, indexed at the bulletin level) each handle network-facility, medical-necessity, experimental-designation, and donor-coverage denials through different reviewer queues. The indexed Administrative Law Judge precedent library that covers Medicare Advantage Subpart M appeals includes the Medicare Advantage transplant line of decisions.

The donor pathway under the Living Donor Protection Act runs on its own clock. The continuity-of-care argument turns on the patient's specific evaluation timeline. Procedural exhaustion missteps foreclose external review. Expedited handling under 45 CFR 147.136(b)(2)(ii)(C) or 42 CFR 422.584 requires a treating-physician attestation that meets the carrier's urgency standard. The family is coordinating a major surgery and a donor at the same time as the appeal.

The patient is on two lists at once. The UNOS list ranks by clinical urgency. The carrier's network list ranks by contract.

Where Apellica's leverage sits

Apellica's review desk indexes carrier behavior across more than two hundred carrier-by-denial-type cells that tracks transplant coverage at every major commercial carrier, the third-party transplant networks (Optum Transplant, INTERLINK, others), and the Medicare Advantage transplant-policy framework. The desk maintains the OPTN policy and the organ-specific society guidance (KDIGO, AASLD, ISHLT, the NKF, NHF, ASTS resources).

Same-day document-request letters go out with the correct CFR cite and the transplant center's listing-evaluation request. Apellica's senior reviewers build the four-part evidence stack, plan-language citation, clinical facts drawn from the transplant center's record, peer-reviewed and society evidence, regulatory hook combining 42 CFR Part 121 with the plan-specific CFR, for every case. Expedited handling is requested where the clinical timeline supports it. A senior reviewer reads every appeal before it goes out.

Initial review is free. There is no upfront fee. Patients are not asked to pay anything until the carrier reverses the denial.

Procedural deadlines and parallel filings

Transplant coverage denials follow the deadlines of the underlying plan. ACA-regulated commercial plans run on the 180-day internal-appeal window under 45 CFR 147.136(b), with external review available under 45 CFR 147.136(d). ERISA self-funded plans run on the 180-day window under 29 CFR 2560.503-1(h). Medicare Advantage runs on the 60-day window under 42 CFR 422.582, with auto-forward to the IRE at Level 2. Medicare fee-for-service covers transplants under Part A and B with specific NCDs; the carrier appeal route runs through the MAC and then OMHA. Medicaid runs through the state fair-hearing process under 42 CFR 431.220.

Where the denial threatens an active clinical timeline (advancing disease, scheduled procedure, donor evaluation in progress), expedited appeal is appropriate. The expedite request is in writing and identifies the specific clinical reason the standard timeframe would jeopardize the patient's health. For ACA plans the standard is 72 hours under 45 CFR 147.136(b)(2)(ii)(C). For Medicare Advantage the standard is 72 hours under 42 CFR 422.584. For ERISA self-funded plans the urgent-care framework at 29 CFR 2560.503-1(m)(1) applies.

Where to ask for help

UNOS, at unos.org, maintains patient-facing transplant information, the transplant center directory, and policy resources. The American Society of Transplantation, at myast.org, publishes society guidance and provider-facing resources. The American Society of Transplant Surgeons, at asts.org, is the surgical-society counterpart. The organ-specific societies (NKF for kidney at kidney.org; AASLD for liver at aasld.org; ISHLT for heart and lung at ishlt.org) publish the clinical guidance the appeal cites. The National Living Donor Assistance Center at livingdonorassistance.org provides donor-related financial-assistance information. State insurance commissioners, indexed at content.naic.org/consumer.htm, handle state-regulated commercial plan complaints. The Department of Labor's EBSA at askebsa.dol.gov handles ERISA inquiries. The HRSA Division of Transplantation provides federal-policy information. Apellica, at apellica.com, prepares evidence-based appeal letters for transplant coverage denials in all 50 states with no upfront fee.

What to do if you have a transplant denial right now

The federal framework supplies the candidate-selection standard. The society guidance supplies the clinical evidence. The carrier's policy supplies the procedural target. The appeal that wins reads all three and assembles the case the listed transplant center has already built.

Most patients and families leave coverage on the table because the three-architecture appeal is more procedural work than they can take on while coordinating the transplant itself.

The Cleveland patient's appeal anchored on his transplant center's listing evaluation, the OPTN policy on candidate selection, and the continuity-of-care doctrine his nephrologist's referral history supported. The carrier reauthorized the local center. His sister donated in early spring.

How the desk takes on a case

Apellica prepares the evidence-based appeal letter for non-oncology transplant coverage denials in all 50 states, at every level of the internal and external appeal process. The patient or family member reviews and approves every word before submission and authorizes carrier communications under a HIPAA-compliant Assignment of Benefits. We are not a law firm. We are not a medical provider. We are not an insurance carrier. We are an independent administrative service that turns a denied claim into a properly documented appeal letter.

Our model is $0 upfront and a flat fee on successful recovery. If the appeal does not reverse, the patient owes nothing for the preparation work. Coverage extends to all 50 states, every commercial carrier, ERISA plans, Medicare Advantage, Medicare fee-for-service, TRICARE, and Medicaid. A senior reviewer reads every case before it goes out.

About the author

The byline is Mark Henderson, a senior reviewer at Apellica. Apellica is based at One World Trade Center, Suite 8500, in New York City, and prepares insurance-denial appeals in every U.S. state and the District of Columbia. The firm is not a law firm, not a medical provider, and not an insurance carrier. Inquiries are handled at press@apellica.com or +1 (888) 777-6120. More at apellica.com.

References

• National Organ Transplant Act of 1984, 42 USC 274.
• 42 CFR Part 121. OPTN.
• 42 CFR 121.4. OPTN policies binding on member transplant centers.
• Organ Procurement and Transplantation Network, candidate-selection and allocation policies.
• United Network for Organ Sharing, transplant center directory and policy resources.
• KDIGO 2020 Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation.
• AASLD Practice Guidance on Evaluation for Liver Transplantation.
• ISHLT Listing Criteria for Heart Transplantation.
• ISHLT International Consensus Document on the Selection of Lung Transplant Candidates.
• ACC/AHA Heart Failure Guidelines.
• American Society of Transplantation, society guidance documents.
• American Society of Transplant Surgeons, surgical society guidance.
• Living Donor Protection Act of 2024.
• 45 CFR 147.136. Internal claims and appeals and external review.
• 45 CFR 156.230. ACA network adequacy.
• 29 CFR 2560.503-1. ERISA claims procedure.
• 42 CFR 422.582. Medicare Advantage reconsideration deadline.
• 42 CFR 422.584. Medicare Advantage expedited reconsideration.
• 42 CFR 431.220. Medicaid fair-hearing procedures.
• Medicare National Coverage Determinations, organ-specific.
• HRSA Division of Transplantation.
• National Living Donor Assistance Center. livingdonorassistance.org.
• National Kidney Foundation. kidney.org.
• American Association for the Study of Liver Diseases. aasld.org.
• International Society for Heart and Lung Transplantation. ishlt.org.
• NAIC Consumer Information Source. content.naic.org/consumer.htm.